A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Clemastine (CLEMSZA)

First FDA approval1992-04-01
Generic availableYes · 2 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$31.6M in CY2024 Part D spend11K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
$3.36/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.87
Across all dosage forms in distribution.
Highest NADAC
$5.43
Range is tight.
Plans with PA
16 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Clemastine used for?

Clemastine is a this drug class medication tracked in Medicare Part D.

Is there a generic for Clemastine?

Yes. 3 ANDAs filed at FDA, 2 generic manufacturers currently shipping.

How much does my plan pay for Clemastine?

Across 329 Part D plans, Clemastine averages $3.87/unit (NADAC). Lowest available: $3.36/unit. Highest in distribution: $5.43/unit.

Is Clemastine on the FDA shortage list?

No. Clemastine is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.